PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.69
Negative D/E while Healthcare median is 0.05. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
2.47
Dangerously high net debt exceeding 1.5x Healthcare median of 0.58. Michael Burry would check for debt covenant compliance and refinancing risks.
-1.27
Negative coverage while Healthcare median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
0.01
Current ratio below 50% of Healthcare median of 2.13. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.